Cutaneous Melanoma Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0040978 (Cutaneous Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03620019Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaTreatment
NCT03767348Study of RP1 Monotherapy and RP1 in Combination With NivolumabTreatment